Regeneron Pharmaceuticals

TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ —  REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72%

TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ — Second Phase 3 trial undertaken in collaboration with NIAID to announce results today,

TARRYTOWN, N.Y., April 9, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of

TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2021 financial

TARRYTOWN, N.Y., March 30, 2021 /PRNewswire/ — Protocol W trial data confirm results from PANORAMA trial showing EYLEA significantly reduced

TARRYTOWN, N.Y., March 23, 2021 /PRNewswire/ —  REGEN-COV also significantly shortened the duration of symptoms by 4 days All doses

TARRYTOWN, N.Y. and WASHINGTON, March 17, 2021 /PRNewswire/ — $250,000 top award goes to Yunseo Choi in nation’s oldest and most prestigious

[unable to retrieve full-text content]

TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/ — Libtayo is the first immunotherapy to demonstrate improved overall survival in

TARRYTOWN, N.Y. and PARIS, March 4, 2021 /PRNewswire/ —  Submission supported by data demonstrating Dupixent significantly reduced severe asthma attacks

TARRYTOWN, N.Y., Feb. 27, 2021 /PRNewswire/ — Single administration of novel antibody cocktail controlled patients’ allergic response to cat allergen,

TARRYTOWN, N.Y., Feb. 26, 2021 /PRNewswire/ — EU member states can utilize the positive CHMP opinion when making national decisions

TARRYTOWN, N.Y., Feb. 25, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial

TARRYTOWN, N.Y. and PARIS, Feb. 22, 2021 /PRNewswire/ —  Libtayo was superior in extending overall survival compared to chemotherapy in

TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ — Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300

TARRYTOWN, N.Y. and PARIS, Feb. 12, 2021 /PRNewswire/ —  Libtayo was superior in extending overall survival compared to chemotherapy even

TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ — Upholds decision by U.S. District Court to invalidate Amgen’s patent claims directed to

TARRYTOWN, N.Y. and PARIS, Feb. 9, 2021 /PRNewswire/ — Following Priority Review Libtayo receives full approval in locally advanced basal

TARRYTOWN, N.Y., Feb. 5, 2021 /PRNewswire/ — Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth

TARRYTOWN, N.Y. and PARIS, Feb. 1, 2021 /PRNewswire/ —  Improvements were noted across key disease measures in certain patients with

TARRYTOWN, N.Y., Jan. 27, 2021 /PRNewswire/ — Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv

TARRYTOWN, N.Y., Jan. 26, 2021 /PRNewswire/ — Reduction in overall infections seen within first week, with 100% prevention of symptomatic

TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2021 /PRNewswire/ — Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious

TARRYTOWN, N.Y., Jan. 19, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full

TARRYTOWN, N.Y., Jan. 12, 2021 /PRNewswire/ —  New agreement covers 1.25 million additional doses of the casirivimab and imdevimab antibody